IAS 2025 included results from two studies from the large US OPERA cohort on people who started injectable CAB/RPV-LA when their viral load was still detectable.
These results are important because even though CAB/RPV-LA is only approved as a switch option in people with viral load <50 copies/mL on oral ART, it is perhaps most likely to benefit people whose viral load is still detectable due to adherence difficulties with oral treatment.
Read the full news story at HIV i-Base.
All HIV i-Base reports from IAS 2025 can be accessed here.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.